Viridian Therapeutics (NASDAQ: VRDN) shares gained 40% Tuesday after the company unveiled positive topline results from the Phase 3 REVEAL-2 clinical trial of elegrobart in chronic thyroid eye disease (TED). The data not only validated the drug’s efficacy across two dosing regimens but also strengthened Viridian’s path toward a Biologics License Application early next year.
Trial Crushes Primary Endpoint
The REVEAL-2 trial cleared its primary endpoint with a highly statistically significant treatment effect. Specifically, elegrobart administered every four weeks (Q4W) and every eight weeks (Q8W) delivered proptosis responder rates of 50% and 54% at Week 24, respectively, compared to just 15% for placebo. Both results landed with overwhelming statistical strength (p<0.0001).
The Q4W dosing regimen also produced a 61% diplopia responder rate at Week 24, sharply outpacing the 38% rate for placebo (p = 0.0118). Furthermore, elegrobart proved generally well tolerated across both dose groups, posting a safety profile consistent with the earlier REVEAL-1 trial — including low rates of hearing impairment, an important consideration for the IGF-1R class.
A Closer Look at the Numbers
REVEAL-2 enrolled 204 patients, randomizing them on a 1:1:1 basis across three arms: elegrobart Q4W (n = 70), elegrobart Q8W (n = 68), and placebo (n = 66). Notably, mean change from baseline in proptosis came in at -1.9 mm for Q4W and -2.1 mm for Q8W, compared to just -0.5 mm for placebo — underscoring a clinically meaningful difference between treatment and control.
Patient-Friendly Delivery
Beyond the efficacy story, elegrobart’s profile carries a clear commercial advantage. The drug is a subcutaneously delivered, half-life-extended monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). Importantly, Viridian plans to launch elegrobart as an at-home autoinjector treatment — a delivery model that could significantly improve patient convenience compared to infusion-based alternatives.
Building Regulatory Momentum
REVEAL-2 marks the second successful pivotal Phase 3 trial for elegrobart, following positive results from REVEAL-1 in active thyroid eye disease. Consequently, Viridian remains on track to submit a Biologics License Application to the FDA in the first quarter of 2027.
In the meantime, the company has another asset advancing on the regulatory front. Veligrotug currently sits under Priority Review at the FDA, with a PDUFA target action date of June 30, 2026 — giving Viridian two near-term shots on goal in the TED market.
Strong Balance Sheet to Support Launch Plans
To fund its commercial and clinical ambitions, Viridian heads into this next phase with substantial firepower. The company reported cash, cash equivalents, and marketable securities of $762.2 million as of March 31, 2026 — a balance sheet that should comfortably support both the upcoming veligrotug PDUFA decision and the planned elegrobart BLA submission and launch readiness work.
The combination of two successful Phase 3 readouts, a differentiated at-home autoinjector strategy, and nearly $800 million in cash helps explain why investors moved aggressively on the news, sending VRDN shares sharply higher in Tuesday trading. For more investor relations information on Viridian Therapeutics please visit www.investors.viridiantherapeutics.com.
The post Viridian Therapeutics Stock Gained 40% on Positive Phase 3 REVEAL-2 Trial Results appeared first on PRISM MarketView.